QARADAKHI, T., L. K. GADANEC, K. R. MCSWEENEY, A. TACEY, V. APOSTOLOPOULOS, I. LEVINGER, K. RIMAROVA, E. E. EGOM, L. RODRIGO, Peter KRUŽLIAK, P. KUBATKA and A. ZULLI. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clinical and Experimental Pharmacology and Physiology. Australia: Blackwell Publishing Australia, 2020, vol. 47, No 5, p. 751-758. ISSN 0305-1870. Available from: https://dx.doi.org/10.1111/1440-1681.13251.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases
Authors QARADAKHI, T. (36 Australia), L. K. GADANEC (36 Australia), K. R. MCSWEENEY (36 Australia), A. TACEY (36 Australia), V. APOSTOLOPOULOS (36 Australia), I. LEVINGER (36 Australia), K. RIMAROVA (703 Slovakia), E. E. EGOM (124 Canada), L. RODRIGO (724 Spain), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution), P. KUBATKA (703 Slovakia) and A. ZULLI (36 Australia).
Edition Clinical and Experimental Pharmacology and Physiology, Australia, Blackwell Publishing Australia, 2020, 0305-1870.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30105 Physiology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.557
RIV identification code RIV/00216224:14110/20:00115986
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/1440-1681.13251
UT WoS 000509618900001
Keywords in English angiotensin-converting enzyme II; cardiovascular disease; diminazene aceturate; endothelial dysfunction; renin angiotensin system
Tags 14110121, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/7/2020 10:04.
Abstract
The renin angiotensin system (RAS) regulates fluid balance, blood pressure and maintains vascular tone. The potent vasoconstrictor angiotensin II (Ang II) produced by angiotensin-converting enzyme (ACE) comprises the classical RAS. The non-classical RAS involves the conversion of Ang II via ACE2 into the vasodilator Ang (1-7) to counterbalance the effects of Ang II. Furthermore, ACE2 converts AngA into another vasodilator named alamandine. The over activation of the classical RAS (increased vasoconstriction) and depletion of the non-classical RAS (decreased vasodilation) results in vascular dysfunction. Vascular dysfunction is the leading cause of atherosclerosis and cardiovascular disease (CVD). Additionally, local RAS is expressed in various tissues and regulates cellular functions. RAS dysregulation is involved in other several diseases such as inflammation, renal dysfunction and even cancer growth. An approach in restoring vascular dysfunction and other pathological diseases is to either increase the activity of ACE2 or reduce the effect of the classical RAS by counterbalancing Ang II effects. The antitrypanosomal agent, diminazene aceturate (DIZE), is one approach in activating ACE2. DIZE has been shown to exert beneficial effects in CVD experimental models of hypertension, myocardial infarction, type 1 diabetes and atherosclerosis. Thus, this review focuses on DIZE and its effect in several tissues such as blood vessels, cardiac, renal, immune and cancer cells.
PrintDisplayed: 6/10/2024 21:59